The probiotic Propionibacterium freudenreichii as a new adjuvant for TRAIL-based therapy in colorectal cancer.

@article{Cousin2016ThePP,
  title={The probiotic Propionibacterium freudenreichii as a new adjuvant for TRAIL-based therapy in colorectal cancer.},
  author={Fabien J. Cousin and Sandrine Jouan-Lanhouet and Nathalie Th{\'e}ret and Catherine Brenner and Elodie Jouan and Gw{\'e}na{\"e}lle Le Moigne-Muller and Marie-Th{\'e}r{\^e}se Dimanche-Boitrel and Gw{\'e}na{\"e}l Jan},
  journal={Oncotarget},
  year={2016},
  volume={7 6},
  pages={7161-78}
}
TNF-Related Apoptosis-Inducing Ligand (TRAIL) is a well-known apoptosis inducer, which activates the extrinsic death pathway. TRAIL is pro-apoptotic on colon cancer cells, while not cytotoxic towards normal healthy cells. However, its clinical use is limited by cell resistance to cell death which occurs in approximately 50% of cancer cells. Short Chain Fatty Acids (SCFA) are also known to specifically induce apoptosis of cancer cells. In accordance, we have shown that food grade dairy… CONTINUE READING
11 Extracted Citations
54 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 11 extracted citations

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 54 references

Two deathinducing human TRAIL receptors to target in cancer: Similar or distinct regulation and function

  • IAM van Roosmalen, WJ Quax, FAE. Kruyt
  • Biochem. Pharmacol
  • 2014
1 Excerpt

Similar Papers

Loading similar papers…